Voxelotor for the treatment of patients with sickle cell disease

11 January 2023 - The Department of Health and Social Care has asked NICE to produce guidance on using voxelotor ...

Read more →

Maribavir for the treatment of patients with a refractory cytomegalovirus infection after transplant

18 January 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...

Read more →

AbbVie and Eli Lilly, two of the world’s largest pharmaceutical companies, have sent a warning signal to the UK government by leaving the voluntary medicines pricing agreement in protest over increasingly punitive revenue clawbacks

16 January 2023 - AbbVie and Lilly have left the UK’s Voluntary Scheme for Branded Medicines Pricing and Access, a ...

Read more →

Angiotensin II acetate for the treatment of patients with vasosuppressor-resistant hypotension caused by septic or distributive shock

16 January 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...

Read more →

Nivolumab in combination with platinum and fluoropyrimidine-based chemotherapy for the first-line treatment of patients with advanced, HER2 negative gastric, gastro-oesophageal junction or oesophageal adenocarcinoma

11 January 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...

Read more →

Mobocertinib succinate for patients with advanced EGFR exon 20 insertion mutation positive non-small-cell lung cancer after platinum-based chemotherapy

4 January 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...

Read more →

NICE recommends a weekly injection for treating growth failure in children

22 December 2022 - This recommendation comes from a pilot to develop simpler, faster evaluations for the appraisal of some treatments. ...

Read more →

NICE recommends Enhertu for more people with advanced breast cancer

20 December 2022 - Hundreds more people eligible for breast cancer drug Enhertu as NICE recommends it for earlier stage ...

Read more →

Avatrombopag maleate for the treatment of patients with primary chronic immune thrombocytopenia

15 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...

Read more →

Esketamine hydrochloride for patients with treatment-resistant depression

14 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...

Read more →

Trifluridine with tipiracil hydrochloride for the treatment of patients with metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after two or more treatments

14 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...

Read more →

Pembrolizumab for the neo-adjuvant and adjuvant treatment of patients with early or locally advanced triple negative breast cancer

14 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...

Read more →

Amivantamab for the treatment of patients with EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy

14 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...

Read more →

Cabozantinib maleate for patients with previously treated advanced hepatocellular carcinoma

14 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...

Read more →

More than 5,200 people could benefit after NICE broadens recommendation on chronic lung disease treatment

14 December 2022 - NICE broadens recommendation on chronic lung disease treatment. ...

Read more →